Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 2Phase 3 Interventional Results available

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

NCT02527343
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
volanesorsen, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

NCT06621017
View directory record Official record
Conditions
Obesity; Overweight
Interventions
ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg
Drug
Lead sponsor
Rose Pharma Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 2 Interventional Results available

POC Study in Partially Responsive Generalized Anxiety Disorder

NCT02310568
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PF-06372865.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Cerritos, California • Encino, California • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)

NCT00127868
View directory record Official record
Conditions
Tinea Capitis
Interventions
oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
Drug
Lead sponsor
Chen, Catherine, M.D.
Other
Eligibility
12 Months to 12 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

NCT04557891
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Active LIFUP Treatment, Sham LIFUP Treatment
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

NCT06102174
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, Active
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 60 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

StaphVAX in Cardiovascular Surgery Patients

NCT00211913
View directory record Official record
Conditions
Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

Improving Preterm Kidney Outcomes With Caffeine

NCT07262060
View directory record Official record
Conditions
Kidney Injury, Pre-Term
Interventions
Caffeine citrate, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Hours to 96 Hours
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

NCT00829582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ETI-204, "Anthim", placebo
Drug · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

NCT00885196
View directory record Official record
Conditions
Moderate and Severe Plaque Psoriasis
Interventions
Placebo, AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
10
States / cities
Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Sonrotoclax, Zanubrutinib, Placebo
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02165215
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
33
States / cities
Orange, California • San Diego, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome

NCT07846215
View directory record Official record
Conditions
Dup15Q Syndrome
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Newleos Therapeutics, Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

NCT03971617
View directory record Official record
Conditions
Parkinson Disease
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Enhancing Efficacy of Mango Polyphenols in Lean and Obese

NCT04970589
View directory record Official record
Conditions
Obesity
Interventions
Mango, Probiotics, Placebo
Other · Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

NCT04176991
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

NCT00540891
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
ALFUZOSIN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Male only
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2007 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Light Therapy for Depression in Adolescent Outpatients

NCT05823090
View directory record Official record
Conditions
Depression, Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 1:40 PM EDT